OSE Immunotherapeutics SA
PAR:OSE

Watchlist Manager
OSE Immunotherapeutics SA Logo
OSE Immunotherapeutics SA
PAR:OSE
Watchlist
Price: 8.89 EUR -0.78% Market Closed
Market Cap: 193.4m EUR
Have any thoughts about
OSE Immunotherapeutics SA?
Write Note

OSE Immunotherapeutics SA
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

OSE Immunotherapeutics SA
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
OSE Immunotherapeutics SA
PAR:OSE
Capital Expenditures
-€250k
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Capital Expenditures
-€26m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Capital Expenditures
-€504k
CAGR 3-Years
-80%
CAGR 5-Years
13%
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Capital Expenditures
-€1.2m
CAGR 3-Years
-111%
CAGR 5-Years
10%
CAGR 10-Years
-13%
Inventiva SA
PAR:IVA
Capital Expenditures
-€565k
CAGR 3-Years
-8%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Capital Expenditures
-€4.1m
CAGR 3-Years
-13%
CAGR 5-Years
-18%
CAGR 10-Years
-17%
No Stocks Found

OSE Immunotherapeutics SA
Glance View

Market Cap
193.5m EUR
Industry
Biotechnology

OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

OSE Intrinsic Value
28.33 EUR
Undervaluation 69%
Intrinsic Value
Price

See Also

What is OSE Immunotherapeutics SA's Capital Expenditures?
Capital Expenditures
-250k EUR

Based on the financial report for Jun 30, 2024, OSE Immunotherapeutics SA's Capital Expenditures amounts to -250k EUR.

What is OSE Immunotherapeutics SA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
7%

The average annual Capital Expenditures growth rates for OSE Immunotherapeutics SA have been -4% over the past three years , 7% over the past five years .

Back to Top